This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Upadacitinib in ankylosing spondylitis

Authoring team

Upadacitinib in ankylosing spondylitis

Upadacitinib, an oral JAK (Janus Kinase) inhibitor

  • engineered for increased selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2
  • used in the management of ankylosing spondylitis

NICE state:

  • upadacitinib is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if:
    • tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
    • the company provides upadacitinib according to the commercial agreement
  • if patients and their clinicians consider upadacitinib to be one of a range of suitable treatments (including secukinumab and ixekizumab), choose the least expensive treatment, taking into account administration costs, dosage, price per dose and commercial arrangements
  • assess response to upadacitinib after 16 weeks of treatment. Continue treatment only if there is clear evidence of response, defined as:
    • a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre-treatment value or by 2 or more units and
    • a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more
  • take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the BASDAI and spinal pain VAS and make any adjustments needed

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.